The new financing will be available for Novocure in four tranches of USD 100 million and provides more flexibility and financial stability to invest in future growth specifically in the area of non-small cell lung cancer.

Pharmakon Advisors, LP is a leading investor in non-dilutive debt for the life sciences industry. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer.